Inactive Instrument

NOVARTIS Share Price London S.E.

Equities

0HKE

CH0012005267

Pharmaceuticals

End-of-day quote London S.E.
- GBX - Intraday chart for NOVARTIS
Sales 2024 * 48.85B 3,896B Sales 2025 * 50.67B 4,040B Capitalization 199B 15,843B
Net income 2024 * 10.2B 814B Net income 2025 * 11.93B 951B EV / Sales 2024 * 4.33 x
Net Debt 2024 * 12.79B 1,020B Net Debt 2025 * 11.32B 903B EV / Sales 2025 * 4.15 x
P/E ratio 2024 *
19.3 x
P/E ratio 2025 *
16.6 x
Employees -
Yield 2024 *
3.71%
Yield 2025 *
3.84%
Free-Float 85.22%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 48 31/12/04
Director of Finance/CFO 59 31/12/02
Chief Tech/Sci/R&D Officer 62 15/05/22
Members of the board TitleAgeSince
Director/Board Member 62 31/12/12
Director/Board Member 65 27/02/20
Chairman 68 31/12/12
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company